BACKGROUND: Indirect pulp capping (IPC) represents a pivotal therapeutic intervention directed toward preservation of pulp vitality, achieved through the placement of a biocompatible, bioactive material over the affected dentin to protect the pulp from further insult and encourage healing. AIM: This study aimed to evaluate the clinical and radiographical success rates of Biodentin versus light-cured mineral trioxide aggregate (MTA) when used as an IPC agents. Evaluation was done on the basis of prognosis of the treatment after a period of 1 year. METHODOLOGY: This randomized controlled clinical trial was based on a cohort of 20 individuals with deep carious lesions being subsequently divided into two experimental groups of ten cases each. Group I - Biodentin and Group II - Light cured-MTA as pulp capping agents, respectively. Clinical and radiographical assessment was done at baseline, 1, 2, 3, 6 months, and 1 year. RESULTS: Statistical analysis with the Chi-square test showed no statistically significant difference between the groups. The overall success rate of 1-year follow-up for both Biodentine group and Light-cured MTA group was 93.33%. CONCLUSION: The results of this randomized controlled clinical trial support promising success of IPC independent of the pulp capping material used as the findings underscore a significant decrease in postoperative pain levels compared to preoperative states across all cases. However, more studies with long-term follow-ups are required.